Brown Rudnick Assists Aktis Oncology in $175M Series B Financing

Brown Rudnick acted as corporate and transactional counsel for biotech company Aktis Oncology in its $175 million Series B financing.

The funding round closed on Sept. 20. RA Capital, RTW Investments and Janus Henderson led the round, which included existing investors MPM Capital, EcoR1 Capital, Vida Ventures, Blue Owl Capital, Bristol-Myers Squibb, Eli Lilly and Merck, among others. New investors included T. Rowe Price, Baker Bros. Advisors, Avidity Partners Management and others.

The Massachusetts-based startup is developing targeted radiopharmaceuticals to treat solid tumor cancers.

Founded by MPM Capital in 2019, Aktis raised $161 million in its Series A financing under Brown Rudnick's guidance.

Partner Michael Cohen led the Brown Rudnick team, which also included associates Tyler Horowitz, Tom Rezach and Rachel Moroknek.